Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Frequency, characteristics, and immunological accompaniments of ataxia in anti-NMDAR antibody-associated encephalitis.
Front Immunol
December 2024
Department of Neurology, University Hospital Ulm, Ulm, Germany.
Introduction: Very rarely, adult NMDAR antibody-associated encephalitis (NMDAR-E) leads to persistent cerebellar atrophy and ataxia. Transient cerebellar ataxia is common in pediatric NMDAR-E. Immune-mediated cerebellar ataxia may be associated with myelin oligodendrocyte glycoprotein (MOG), aquaporin-4 (AQP-4), kelch-like family member 11 (KLHL11), and glutamate kainate receptor subunit 2 (GluK2) antibodies, all of which may co-occur in NMDAR-E.
View Article and Find Full Text PDFOphthalmic Manifestations of Angiolymphoid Hyperplasia with Eosinophilia: A Systematic Review and Pooled Analysis of 86 Cases.
Ophthalmic Plast Reconstr Surg
December 2024
Department of Pathology, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India.
Purpose: This systematic review aims to consolidate evidence on ophthalmological manifestations of angiolymphoid hyperplasia with eosinophilia, focusing on its presentation, diagnosis, and management.
Methods: Preferred reporting items for systematic reviews and meta-analyses-adherent systematic review was conducted across 3 databases from inception until September 2024. Case reports and series detailing angiolymphoid hyperplasia with eosinophilia in ocular structures were included.
Efficacy, Safety, and Recurrence in Older Thyroid Eye Disease Patients Undergoing Teprotumumab Treatment.
Ophthalmic Plast Reconstr Surg
December 2024
Israel Englander Department of Ophthalmology, Weill Cornell Medical College, New York City, New York, U.S.A.
Increasing life expectancy and an aging population have preserved quality of life decisions into older adulthood, defined by some clinical standards as greater than 75 years of age. While teprotumumab may represent a breakthrough in the treatment of thyroid eye disease, the teprotumumab phase III trial included only 2 patients aged over 75. Four female patients between the ages of 78 and 86-of whom 3 completed 8 infusions and 1 completed 7 infusions before discontinuation-were included in our study with a mean initial Clinical Activity Score score of 5.
View Article and Find Full Text PDFBotulinum Toxin Treatment in Thyroid Eye Disease: A Systematic Review and Meta-analysis.
Ophthalmic Plast Reconstr Surg
December 2024
Department of Ophthalmology and Visual Sciences, Montefiore Medical Center, Albert Einstein College of Medicine.
Purpose: Thyroid eye disease-related retraction and strabismus treatment is complicated by the activity level of the disease. Botulinum toxin injection can provide relief of symptoms in lieu of, or while waiting for surgery, radiation, or alternative medications. This study reviews techniques, outcomes, and effectiveness of botulinum toxin usage in thyroid eye disease.
View Article and Find Full Text PDFHypertrophic pachymeningitis with cranial nerve palsy as the initial symptom: A case report.
Medicine (Baltimore)
December 2024
Department of Ophthalmology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
Article Synopsis
- Hypertrophic pachymeningitis (HP) is a rare condition characterized by inflammation and thickening of the dura mater, often leading to severe symptoms like headaches and cranial nerve defects, or sometimes presenting without symptoms.
- The case details a 26-year-old female who was diagnosed with HP after experiencing diplopia due to abducens nerve palsy, which significantly impacted her vision.
- Following treatment with methylprednisolone pulse therapy, the patient showed substantial recovery, highlighting the importance of understanding this rare condition and its varied clinical presentations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!